Edition:
United Kingdom

Zai Lab Ltd (ZLAB.OQ)

ZLAB.OQ on NASDAQ Stock Exchange Global Market

16.37USD
19 Oct 2018
Change (% chg)

$-0.10 (-0.61%)
Prev Close
$16.47
Open
$16.48
Day's High
$16.51
Day's Low
$16.16
Volume
32,768
Avg. Vol
58,444
52-wk High
$30.00
52-wk Low
$14.29

Latest Key Developments (Source: Significant Developments)

Zai Lab Appoints Tao Fu As President & COO
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Zai Lab Ltd ::ZAI LAB APPOINTS INDUSTRY LEADER TAO FU AS PRESIDENT & CHIEF OPERATING OFFICER, EXPANDS US PRESENCE.ZAI LAB LTD - ANNOUNCED APPOINTMENT OF TAO FU AS PRESIDENT AND CHIEF OPERATING OFFICER, EFFECTIVE SEPT 24, 2018.  Full Article

Novocure And Zai Lab Announce Strategic Collaboration
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Zai Lab Ltd ::NOVOCURE AND ZAI LAB ANNOUNCE STRATEGIC COLLABORATION WITH A LICENSE AGREEMENT FOR TUMOR TREATING FIELDS IN GREATER CHINA.ZAI LAB LTD - ZAI LAB WILL SUPPORT ENROLLMENT OF CHINESE PATIENTS TO CERTAIN CLINICAL TRIALS INVESTIGATING TUMOR TREATING FIELDS.ZAI LAB LTD - NOVOCURE WILL RECEIVE A $15 MILLION UPFRONT PAYMENT.ZAI LAB LTD - NOVOCURE IS ALSO ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS UPON ACHIEVEMENT OF CERTAIN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ZAI LAB LTD - NOVOCURE GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO COMMERCIALIZE TUMOR TREATING FIELDS IN CHINA, HONG KONG, MACAU AND TAIWAN.ZAI LAB LTD - ZAI LAB WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS IN GREATER CHINA.  Full Article

Zai Lab Files For Offering ADSs For A Total Price To Public Of $150 Mln
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Zai Lab Ltd ::ZAI LAB LTD FILES FOR OFFERING ADSS FOR A TOTAL PRICE TO PUBLIC OF $150 MILLION - SEC FILING.ZAI LAB LTD SAYS J.P. MORGAN, CITIGROUP, JEFFERIES & LEERINK PARTNERS ARE AMONG UNDERWRITERS FOR OFFERING.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Photo

U.S.-listed Chinese biotech Zai Lab plans Hong Kong float: sources

HONG KONG (Reuters/IFR) - Zai Lab Ltd is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said.